Showing results (131-140 of 257) with videos related to
Sort By:
Pageof 26
Cancer Science|January 11, 2011
Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological featuresYuko Ishikawa, Jun Horiguchi, Hiroyuki Toya, et al.BMC Cancer|September 9, 2015
ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumabSasagu Kurozumi, Kenichi Inoue, Hiroyuki Takei, et al.American Heart Journal|November 24, 2007
Comprehensive evaluation of noncalcified coronary plaque characteristics detected using 64-slice computed tomography in patients with proven or suspected coronary artery diseaseToshiro Kitagawa, Hideya Yamamoto, Norihiko Ohhashi, et al.Scientific Reports|November 15, 2019
Clinicopathological values of PD-L1 expression in HER2-positive breast cancerSasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, et al.Scientific Reports|February 9, 2019
Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancerSasagu Kurozumi, Kenichi Inoue, Hiroshi Matsumoto, et al.Journal of Computer Assisted Tomography|April 22, 2006
Endovascular therapy of pulmonary arteriovenous malformations: Utility of 16-detector-row computed tomography pulmonary angiography as a pre-embolization surveyNobuhiko Hirai, Naoyuki Toyota, Hideaki Kakizawa, et al.Journal of Child and Adolescent Psychopharmacology|June 21, 2013
Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label studyRei Wake, Tsuyoshi Miyaoka, Takuji Inagaki, et al.The Journal of Surgical Research|November 29, 2017
Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancerTakashi Ishikawa, Kouhei Akazawa, Yoshie Hasegawa, et al.In Vivo (Athens, Greece)|November 4, 2020
Implications of Topoisomerase (TOP1 and TOP2α) Expression in Patients With Breast CancerMisato Ogino, Takaaki Fujii, Yuko Nakazawa, et al.BMC Cancer|November 7, 2020
Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancerKeiko Yanai, Takaaki Fujii, Jun Horiguchi, et al.Pageof 26